% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • accugrowth accugrowth Jun 26, 2013 10:46 PM Flag

    NCT01096784 ROP Study Suspended

    This study is ongoing, but not recruiting participants.
    Insulin-Like Growth Factor I (IGF-I) in the Prevention of Complications of Preterm Birth
    Study Number: NCT01096784

    The reason for the suspension can be twisted in many different directions. The question for investors is whether Shire decided to NOT pay the option price of $10 million for the rights. No PR. It does not matter who is sitting in the CEO seat; INSM investors are mushrooms and kept in the dark. However, this event may explain the share price decrease this week.

    Do not kill the messenger. I no longer have table stakes in this gambling game that just happens to be listed on NASDAQ.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • accugrowth . Shire has announced they will continue the trial and bought Premicure from their private investors and will continue the Phase2 trial .The trial results are due in Dec.If you have additional info beyond conjecture, a few may be interested, Good Luck

      • 1 Reply to terry_amln
      • Shire had the OPTION to purchase the ROP indication from INSM in June. That is a different statement from actually sending the $10 million in cash. We will not have clarity until August when INSM reports their quarterly numbers. Why would Shire pay when the study in not moving forward?

        I do not trust the INSM management. The dilution experienced by INSM investors last year has been proven as the wrong move by the BOD since the share price has increased by almost 3X since then. The company had zero need for the additional cash at the time. Imagine being able to sell those shares now for $11/share instead of the $4.15/share that they got just a few months ago. Why should investors trust INSM management?????

        I left at the $4.50-$4.80 range with a good profit and reduced my risk as a result. I lost nothing and I am not posting out of some virtual temper tantrum. Current INSM investors are gambling. IMHO

        There are some on this thread who are twisting the news that the freeze on recruiting subjects for the ROP study is good news. However, they are not very clear as to what positive outcome might result from zero additional data.

        The INSM benefit from ROP is capped at $10 million (potential from Shire). Positive news about PremiPlex for ROP will not otherwise impact the INSM bottom line. Bad news can mean that INSM does not even get the $10 million. I see RISK. Make your own decision.

    • Fraud! Liar! #$%$.

    • Suspended??!! The website says exact the opposite: "Ongoing". In fact, why don't you post the exact header: "This study is ongoing, but not recruiting participants." It's no longer recruiting participants because the treatment was completed, and infants treated from June 2010 to December 2013 are due to "Long term follow up [ Time Frame: At 2.5 and 5.5 years of age ]"

      "Estimated Enrollment: 80
      Study Start Date: June 2010
      Estimated Study Completion Date: December 2013
      Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)"

      You really should read the contents of the links before you post. I don't think anyone will call you a "messenger", but most will definitely call you a "clown"

    • "The reason for the suspension can be twisted in many different directions"
      Why do you use the word "suspension" when clinicaltrials doesn't? Ongoing but not recruiting means just what it says. When a trial is suspended it says suspended!

      Sentiment: Strong Buy

    • This is due to transfer to Shire Robert. I tell you what buddy, this is a lot like "you are out at $4" post a few months ago. Hummm, missed that one didn't you. We are not going to shoot the messenger, we are too busy laughing at the messenger. al

14.04-0.03(-0.21%)Oct 21 4:00 PMEDT